Skip to main content

Quality of life and psychological distress in patients with acute myeloid leukemia (AML).

Publication ,  Conference
Markovitz, N; Waldman, L; Carp, J; Traeger, L; Abel, GA; Greer, J; Fathi, AT; Steensma, DP; LeBlanc, TW; DeAngelo, DJ; Wadleigh, M; Hobbs, G ...
Published in: Journal of Clinical Oncology
December 1, 2018

154 Background: Older patients with AML face difficult treatment decisions as they can be treated either with multi-drug ‘intensive’ chemotherapy requiring a prolonged hospitalization, or ‘non-intensive’ chemotherapy. Although clinicians often perceive intensive chemotherapy as more burdensome, studies comparing older patients’ quality of life (QOL) and psychological distress while receiving these treatments are lacking. Methods: We conducted a longitudinal study of older patients (≥ 60 years) newly diagnosed with AML receiving intensive (i.e. 7+3: cytarabine/anthracycline combination) or non-intensive (i.e., hypomethylating agents) chemotherapy at two tertiary care hospitals. We assessed patient’s QOL [Functional Assessment of Cancer Therapy-Leukemia], and psychological distress [Hospital Anxiety and Depression Scale [HADS]] at baseline and 2, 4, 8, 12, and 24 weeks after diagnosis. We compared the proportion of patients in each group reporting clinically significant depression or anxiety (HADS subscale cut off ≥ 7) and used mixed linear effects models to compare QOL and psychological distress longitudinally between groups. Results: We enrolled 75.2% (100/133) of eligible patients within 72 hours of initiating intensive (n = 50) or non-intensive (n = 50) chemotherapy. Baseline QOL, depression, or anxiety symptoms did not differ between the groups. At baseline, 33.33% (33/100) and 30% (30/100) of the overall cohort reported clinically significant depression and anxiety, respectively, with no differences between groups. At 4 weeks, 41.98% (34/81) of patients in the overall cohort reported clinically significant depression, with no differences between groups. In mixed linear effects models, there were no differences in QOL (β = -0.71, SE = 1.12, p = 0.527), depression (β = 0.24, SE = 0.20, p = 0.226), or anxiety (β = -0.16, SE = 0.19, p = 0.386) symptoms over all time points. Conclusions: Older patients with AML receiving intensive and non-intensive chemotherapy experience similar QOL and high rates of psychological distress. These findings underscore the need to develop supportive care interventions for older patients with AML, regardless of their initial treatment strategy.

Duke Scholars

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

December 1, 2018

Volume

36

Issue

34_suppl

Start / End Page

154 / 154

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences
 

Citation

APA
Chicago
ICMJE
MLA
NLM
Markovitz, N., Waldman, L., Carp, J., Traeger, L., Abel, G. A., Greer, J., … El-Jawahri, A. (2018). Quality of life and psychological distress in patients with acute myeloid leukemia (AML). In Journal of Clinical Oncology (Vol. 36, pp. 154–154). American Society of Clinical Oncology (ASCO). https://doi.org/10.1200/jco.2018.36.34_suppl.154
Markovitz, Netana, Lauren Waldman, Julia Carp, Lara Traeger, Gregory A. Abel, Joseph Greer, Amir Tahmasb Fathi, et al. “Quality of life and psychological distress in patients with acute myeloid leukemia (AML).” In Journal of Clinical Oncology, 36:154–154. American Society of Clinical Oncology (ASCO), 2018. https://doi.org/10.1200/jco.2018.36.34_suppl.154.
Markovitz N, Waldman L, Carp J, Traeger L, Abel GA, Greer J, et al. Quality of life and psychological distress in patients with acute myeloid leukemia (AML). In: Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 154–154.
Markovitz, Netana, et al. “Quality of life and psychological distress in patients with acute myeloid leukemia (AML).Journal of Clinical Oncology, vol. 36, no. 34_suppl, American Society of Clinical Oncology (ASCO), 2018, pp. 154–154. Crossref, doi:10.1200/jco.2018.36.34_suppl.154.
Markovitz N, Waldman L, Carp J, Traeger L, Abel GA, Greer J, Fathi AT, Steensma DP, LeBlanc TW, DeAngelo DJ, Wadleigh M, Hobbs G, Brunner AM, Amrein PC, Stone RM, Temel JS, El-Jawahri A. Quality of life and psychological distress in patients with acute myeloid leukemia (AML). Journal of Clinical Oncology. American Society of Clinical Oncology (ASCO); 2018. p. 154–154.

Published In

Journal of Clinical Oncology

DOI

EISSN

1527-7755

ISSN

0732-183X

Publication Date

December 1, 2018

Volume

36

Issue

34_suppl

Start / End Page

154 / 154

Publisher

American Society of Clinical Oncology (ASCO)

Related Subject Headings

  • Oncology & Carcinogenesis
  • 3211 Oncology and carcinogenesis
  • 1112 Oncology and Carcinogenesis
  • 1103 Clinical Sciences